|
Oct 9
|
BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
|
|
Sep 18
|
BioCardia Regains Full Compliance with Nasdaq Listing Requirements
|
|
Aug 7
|
BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024
|
|
Jul 30
|
BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family
|
|
Jul 25
|
Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure
|
|
May 21
|
BioCardia Announces Reverse Stock Split
|
|
May 15
|
BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ...
|
|
May 14
|
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
|
|
May 14
|
Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable
|
|
May 9
|
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
|
|
May 1
|
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
|
|
Apr 25
|
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
|
|
Apr 2
|
Insiders Are Buying These 11 Penny Stocks
|
|
Apr 1
|
BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript
|
|
Mar 29
|
BioCardia Full Year 2023 Earnings: Misses Expectations
|
|
Mar 28
|
Q4 2023 BioCardia Inc Earnings Call
|
|
Mar 27
|
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
|
|
Mar 20
|
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
|
|
Mar 13
|
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
|
|
Mar 12
|
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
|